Skip to Content
Merck
All Photos(1)

Key Documents

SML3008

Sigma-Aldrich

SCIO-469

≥98% (HPLC)

Synonym(s):

2-(6-Chloro-5-((2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl)-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide, 6-Chloro-5-[[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-N,N,1-trimethyl-a-oxo-1H-indole-3-acetamide, SCIO 469, SCIO469, Scios 469, Scios-469, Scios469, Talmapimod

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C27H30ClFN4O3
CAS Number:
Molecular Weight:
513.00
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(C(C1=CN(C2=C1C=C(C(Cl)=C2)C(N3[C@@H](CN([C@H](C3)C)CC4=CC=C(C=C4)F)C)=O)C)=O)N(C)C

InChI

1S/C27H30ClFN4O3/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28/h6-11,15-17H,12-14H2,1-5H3/t16-,17+/m0/s1

InChI key

ZMELOYOKMZBMRB-DLBZAZTESA-N

Biochem/physiol Actions

SCIO-469 (Talmapimod) is an orally active, potent and selective mitogen-activated protein kinase (MAPK) p38alpha (p38α, MAPK14) inhibitor (IC50 = 9 nM; 10-fold over p38β, >2000-fold over 20 other kinases) with no significant affinity toward a panel of 70 enzymes and receptors. SCIO-469 inhibits multiple myeloma (MM) growth in mice in vivo (150 or 450 mg/kg powder diet; 5T2MM and 5T33MM) and augments proteasome inhibitor in a murine plasmacytoma model of MM (0.2 mg bortezomib/kg i.v. twice weekly with 30 mg SCIO-469/kg b.i.d. p.o.; RPMI8226).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Yuan-Feng Lin et al.
Journal of cellular and molecular medicine, 22(4), 2458-2468 (2018-02-03)
Paclitaxel-based chemotherapy is a common strategy to treat patients with triple-negative breast cancer (TNBC). As paclitaxel resistance is still a clinical issue in treating TNBCs, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service